Type of information: Company acquisition
Acquired company: Alizé Pharma (France)
Acquiring company: Millendo Therapeutics (USA - Mich)
- • On December 20, 2017, Millendo Therapeutics,announced that it has acquired Alizé Pharma SAS in a stock-based transaction. The company will operate as Millendo Therapeutics, Inc. in the United States and as Millendo Therapeutics SAS in France and Europe where it will continue to operate the former Alizé Pharma SAS facilities, maintain its capabilities and team and serve as Millendo’s European research and development base. Thierry Abribat, D.V.M., Ph.D., the founder and President of the Alizé Pharma companies, will join the Board of Directors of Millendo Therapeutics. Olivier Martinez from Bpifrance and Gilles Alberici from initiative Octalfa will be appointed as board observers.
- Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. The company is currently advancing nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. This acquisition adds livoletide (previously known as AZP-531) to Millendo's pipeline. The compound has demonstrated positive results in reducing hyperphagia in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in Prader-Willi Syndrome (PWS) in 2016. Livoletide has been granted orphan drug designation in PWS by the FDA and has received a positive opinion from the European Medicines Agency (EMA) for orphan drug status.
Related: Endocrine diseases - Hormonal diseases